Oncotype DX® breast cancer test achieves positive reimbursement in Switzerland

Genomic Health announced that starting on January 1, 2015, the Oncotype DX breast cancer test will be covered in Switzerland through the mandatory health insurance system. This means that patients with early-stage, hormone receptor-positive, HER2 negative, invasive breast cancer with up to three positive lymph nodes will have access to the Oncotype DX breast cancer test to help determine whether they are likely to benefit from chemotherapy in addition to hormonal therapy.

View PDF

Find an actor

ORTHOMANUFACTURE 201820.06.2018

European event for implants and surgical Instruments manufacturing technologies. Orthopaedics, traumatology, spine,...

Interview du nouveau Président de BioAlps par l'Agefi

Philippe D. Monnier a parlé avec Claude Clément, nouveau Président de BioAlps, de son nouveau rôle et sa vision...
Print this page Download this page (PDF) Recommend this page to a friend

Contact us

BioAlps Association
Ch. du Pré-Fleuri 3
CH - 1228 Plan-les Ouates
+41 22 304 40 40
+41 22 304 40 70

Subscribe to our newsletter

Find us on LinkedIn